Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases.

Intercept Pharmaceuticals' vision is to create a world where chronic liver diseases can be prevented or effectively managed.

Intercept has received numerous awards and recognitions for its research and development of drugs to treat chronic liver diseases. These include awards from the American Liver Foundation, National Coalition for Research on Cholangiopathies and the International Liver Transplantation Society.